XML 30 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES
12 Months Ended
Dec. 31, 2016
INCOME TAXES [Abstract]  
INCOME TAXES
NOTE 10 - INCOME TAXES

Income tax expense differs from the statutory amounts as follows:

 
2016
  2015 
       
Income taxes at U.S. statutory rate
 
$
(7,437,000
)
 
$
(4,939,000
)
Current year reserve
  
7,423,000
   
6,257,000
 
Other
  
14,000
   
(1,318,000
)
         
Total tax expense
 
$
-
  
$
-
 
 
Deferred taxes are provided for the temporary differences between the financial reporting bases and the tax bases of our assets and liabilities. The temporary differences that give rise to deferred tax assets and liabilities were as follows:
 
 
December 31,
 
 
2016
  2015 
Deferred tax assets (liabilities)
      
Net operating loss carryforwards
 
$
73,864,000
  
$
68,636,000
 
General business credit carryforwards
  
2,557,000
   
2,497,000
 
State credits
  
3,089,000
   
2,055,000
 
Property, equipment and goodwill
  
(23,000
)
  
(25,000
)
Stock options
  
6,450,000
   
3,678,000
 
Derivatives
  
(92,000
)
  
(92,000
)
Deferred revenue
  
1,464,000
   
1,669,000
 
Intangible assets
  
228,000
   
595,000
 
Accrued interest
  
253,000
   
253,000
 
Other
  
231,000
   
231,000
 
Gross deferred tax assets
  
88,021,000
   
79,497,000
 
Valuation allowance
  
(88,021,000
)
  
(79,497,000
)
Net deferred taxes
 
$
-
  
$
-
 

At December 31, 2016, we had approximately $217,246,000 of net operating loss carryforwards and approximately $2,557,000 of general business credit carryforwards. These carryforwards expire as follows:

 
Net operating
loss carryforwards
  
General business
credit carryforwards
 
2017
 
$
-
  
$
-
 
2018
  
3,324,000
   
112,000
 
2019
  
3,306,000
   
95,000
 
Thereafter
  
210,616,000
   
2,350,000
 
 
 
$
217,246,000
  
$
2,557,000
 

As a result of a merger on January 25, 1996, a change in control occurred for federal income tax purposes, which limits the utilization of pre-merger net operating loss carryforwards of approximately $3,100,000 to approximately $530,000 per year.

Additionally, we acquired MacroChem Corporation on February 25, 2009 and Somanta Pharmaceuticals, Inc. on January 4, 2008. Both corporations were loss companies at the time of the acquisition. Therefore, the net operating losses related to those acquisitions may be subject to annual limitations as provided by Internal Revenue Code Sec. 382.